OncoMatch

OncoMatch/Clinical Trials/NCT05804370

Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)

Is NCT05804370 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies Gleolan for ovarian cancer.

Phase 3RecruitingNX Development CorpNCT05804370Data as of May 2026

Treatment: GleolanThis Phase 3 study is designed to investigate the safety, diagnostic performance, and clinical usefulness of Gleolan for the real-time detection and visualization of epithelial ovarian cancer tumors during debulking surgery. The study is planned to run for about 18 months with individual study participation lasting about two (2) weeks.

Check if I qualify

Extracted eligibility criteria

Cancer type

Ovarian Cancer

Prior therapy

Cannot have received: chemotherapy

Patient has had chemotherapy, tumor resection or radiation treatment within 21 days prior to surgery.

Cannot have received: tumor resection

Patient has had chemotherapy, tumor resection or radiation treatment within 21 days prior to surgery.

Cannot have received: radiation therapy

Patient has had chemotherapy, tumor resection or radiation treatment within 21 days prior to surgery.

Lab requirements

Blood counts

normal organ and bone marrow function

Kidney function

Creatinine: Below upper limit of normal OR Creatinine clearance: >60 mL/min/1.73 m2 for participants with creatinine levels above institutional normal

Liver function

Bilirubin: Below upper limit of normal; AST (SGOT): < 2.5 X institutional upper limit of normal; ALT (SGPT): < 2.5 X institutional upper limit of normal

Study participants must have normal organ and bone marrow function and be appropriate surgical candidates per site SoC. Bilirubin: Below upper limit of normal AST (SGOT): < 2.5 X institutional upper limit of normal ALT (SGPT): < 2.5 X institutional upper limit of normal Creatinine: Below upper limit of normal OR Creatinine clearance: >60 mL/min/1.73 m2 for participants with creatinine levels above institutional normal

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • Mayo Clinic Arizona · Phoenix, Arizona
  • Luminis Health Anne Arundel Medical Center · Annapolis, Maryland
  • University of Maryland · Baltimore, Maryland
  • Mayo Clinic Methodist Campus · Rochester, Minnesota
  • Mount Sinai · New York, New York

Showing up to 5 US sites. See all sites on ClinicalTrials.gov →

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify